2024-09-26 - Analysis Report
## TELA Bio Inc. (TELA) Stock Analysis Report

**Company Overview:** TELA Bio Inc. is a medical device company focused on developing and commercializing innovative bioresorbable surgical implants for the treatment of hernia repair.

**Performance Analysis:**

**1. Performance Comparison:**

* **Cumulative Return:** TELA has a cumulative return of -65.08%, significantly underperforming the S&P 500 (VOO) with a cumulative return of 89.38%.
* **Relative Performance:** This means TELA has underperformed VOO by a staggering 154.46%. This places TELA at the lowest point in its historical performance relative to the S&P 500. 

**2. Recent Price Action:**

* **Closing Price:** $2.32
* **5-Day Moving Average:** $2.55
* **20-Day Moving Average:** $2.69
* **60-Day Moving Average:** $3.62

TELA's price is currently below all three moving averages, indicating a downward trend in the short-term.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 30.39. This suggests that TELA is in oversold territory, but it is still below the 30 level, which indicates a potential for further decline.
* **PPO (Percentage Price Oscillator):** 0.39. This is a positive signal, indicating that the price momentum is starting to pick up. 
* **Delta_Previous_Relative_Divergence:** -2.75. This suggests that the recent short-term price action is bearish, as the relative divergence is negative. 
* **Expected Return:** 0.0%. This is a very low expected return, reflecting the current market sentiment. 

**4. Recent Earnings and Forecasts:**

| Date        | EPS  | Revenue       |
|-------------|------|---------------|
| 2024-08-13  | -0.51 | $0.02 Billion |
| 2024-05-10  | -0.23 | $0.02 Billion |
| 2023-11-13  | -0.45 | $0.02 Billion |
| 2023-08-10  | -0.46 | $0.01 Billion |
| 2024-08-13  | -0.46 | $0.01 Billion |

TELA has consistently reported negative earnings, demonstrating a lack of profitability. While revenue has remained relatively stable, the company's inability to turn a profit is a significant concern for investors. 

**5. News and Recent Issues:**

* **FINBOLD** reports that TELA is facing increasing competition from other medical device companies.
* **Analyst opinions** are generally bearish on TELA, citing concerns about its financial performance and lack of a clear path to profitability.
* **Performance highlights** reveal that TELA's stock has been on a downward trend for several months, reflecting the market's lack of confidence in the company's future.

**6. Summary of Analysis:**

TELA Bio Inc. is currently facing significant challenges. The stock has significantly underperformed the market, its price is in a downward trend, and its financial performance is weak. Technical indicators suggest that the short-term outlook is bearish, and analyst opinions reflect a lack of confidence in the company's future. While the recent PPO signal is positive, the overall picture suggests that investors should proceed with caution.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investing in the stock market involves risk and investors should always conduct their own due diligence before making any investment decisions. 
